Mumps Keratoconjunctivitis In A Young Adult: A Case Report.
Published 2022 - 40th Congress of the ESCRS
Reference: PO274 | Type: ESCRS 2022 - Posters | DOI: 10.82333/rbtf-x405
Authors: Mohcine El Mhadi* 1 , Meryem Boughanim 1 , Mohamed Mellaoui 1 , Ahmed Alami 1 , Adil Bouzidi 1 , Aziz El ouafi 1 , Said Iferkhass 1
1Ophthalmology department,Military hospital Moulay Ismail of Meknes,Meknes,Morocco
Purpose
This disease is most often benign but it is very contagious.
Thanks to vaccination, it is nevertheless increasingly rare.
Mumps causes inflammation of the glands. Most of the time, the disease is localized only at the parotid level.
The risk is represented by the other locations: testicle, pancreas, myocardium, meninge, brain.
the purpose of this work is to report through this case, the ocular localization of mumps in a young adult, which is exceptional.
Setting
Methods
A visual acuity of 8/10 P2 in both eyes.
Diffuse conjunctival inflammation with clear secretions.
Follicular conjunctivitis and paralimbic superficial punctate keratitis, especially lower.
General examination finds:
A temperature of 37.8. A bilateral painful swelling, between the earlobe and the jaw in favor of parotitis.
Serology detected the presence of mumps antibodies: IgM and IgG are positive.
The patient was put on: Twice-daily eye wash with saline solution, antiseptic eye drops, healing ointment with vitamin A and artificial tears without preservatives.
A systemicl treatment combining: Paracetamol, vitamin C with mouth care.
The evolution was spectacular.
Results
The diagnosis is most of the time only clinical, the attack of two salivary glands immediately or successively signing the diagnosis of mumps.
Serology can also, in case of doubt, contribute to the diagnosis (search for IgM and rise in IgG using an ELISA test).
Conclusions
The best treatment and vaccine prevention. The vaccine is part of the measles-mumps-rubella (MMR) triple vaccine. This compulsory vaccine is carried out at 12 months with a booster between 16 and 18 months.
It can even be carried out from 6 or 9 months in the event of high risk or if the infant is in the community before 12 months. It confers 95% immunity and is well tolerated.